 Yes, I think that the key part of that is in oncology, where there is the most new therapies being brought forward, they're able to use what's called a surrogate endpoint, meaning can they measure the efficacy of the drug before looking at the survival of the patient? And that allows them to take advantage of the accelerated approval pathway through the FDA.